Omics derived biomarkers and novel drug targets for improved intervention in advanced prostate cancer

Maria Frantzi*, Marie C. Hupe, Axel S. Merseburger, Joost P. Schanstra, Harald Mischak, Agnieszka Latosinska

*Corresponding author for this work
1 Citation (Scopus)


Prostate cancer (PCa) is one of the most frequently diagnosed malignancies, and the fifth leading cause of cancer related mortality in men. For advanced PCa, radical prostatectomy, radiotherapy, and/or long-term androgen deprivation therapy are the recommended treatment options. However, subsequent progression to metastatic disease after initial therapy results in low 5-year survival rates (29%). Omics technologies enable the acquisition of high-resolution large datasets that can provide insights into molecular mechanisms underlying PCa pathology. For the purpose of this article, a systematic literature search was conducted through the Web of Science Database to critically evaluate recent omics-driven studies that were performed towards: (a) Biomarker development and (b) characterization of novel molecular-based therapeutic targets. The results indicate that multiple omics-based biomarkers with prognostic and predictive value have been validated in the context of PCa, with several of those being also available for commercial use. At the same time, omics-driven potential drug targets have been investigated in pre-clinical settings and even in clinical trials, holding the promise for improved clinical management of advanced PCa, as part of personalized medicine pipelines.

Original languageEnglish
Article number658
Issue number9
Publication statusPublished - 09.2020

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)


Dive into the research topics of 'Omics derived biomarkers and novel drug targets for improved intervention in advanced prostate cancer'. Together they form a unique fingerprint.

Cite this